2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592

S. Gettinger,M. Schenker,J. De Langen, J.R. Fischer, D. Morgensztern,T-E. Ciuleanu, T. Beck,J. De Castro Carpeno,C. Schumann, X. Yang, B. Telivala, K. Deschepper,E. Nadal,K. Schalper, T. Spires,D. Balli,A. Nassar, S. Karam, A. Bhingare, D.R. Spigel

Immuno-Oncology and Technology（2022）

引用 0|浏览4

暂无评分

摘要

A high unmet need remains for predictive biomarkers for efficacy in patients (pts) treated with immunotherapy. Here we report primary results from Parts 1 and 2 of CheckMate 592 (NCT03001882), an open-label, phase 2 trial exploring the association of biomarkers with efficacy of 1L NIVO + IPI in pts with mNSCLC.

查看译文

关键词

nivolumab,lung cancer,nivolumab,ipilimumab,first-line,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要